October 30, 2018 Licensing, IP, and Legal

DefiniGEN licenses Broad Institute CRISPR-Cas9 gene editing technology for optimized metabolic disease drug development

Cambridge, UK – 30th October 2018: DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes. Broad Institute CRISPR-Cas9 technology will be combined with DefiniGEN’s best-in-class induced Pluripotent Stem Cell (iPSC)... Read more

September 10, 2018 PR/Corporate

DefiniGEN strengthens Board with the appointment of Professor Sir John Savill

Cambridge, UK, 10th September 2018: DefiniGEN, the world leader in human iPSC differentiation and disease modelling, today announces the appointment of Professor Sir John Savill as a Non-Executive Director of the Board. Sir John will bring his expertise in translational science to DefiniGEN enabling the company to accelerate the development of new products and services which can... Read more